=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
Gordon Research Conference
B I O C A T A L Y S I S
Kimbal Union Academy * Meriden, NH, USA * 7-12 July 1996
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
http://w3.argotech.com/argotech/biocatalysis
I am posting this message to inform you of this years=92 Gordon Research =
Conference on Biocatalysis. The Conference will be held 7-12 July 1996 =
at Kimbal Union Academy in Meriden, New Hampshire, USA. The Conference =
brings together an interdisciplinary group of biologists, chemists, and =
engineers for a full week of intense discussion and examination of the =
frontiers of Biocatalysis. We welcome your application for =
participation in year=92s conference. Also, we would be grateful if you =
would forward a copy of this message to people that you think might be =
interested in attending.
The subject of the Biocatalysis Conference is synthetically useful =
reactions and processes catalyzed by enzymes or whole cells. We will =
address three main themes:
=B7 new uses of existing enzymes (e.g., lipases, oxidases, and aldolases);
=B7 discovery of new enzymes (e.g., epoxide hydrolases, P-450 =
hydroxylases, oxynitrilases, thermophilic organisms); and
=B7 structure and protein engineering of enzymes (e.g., new structures of =
proteases, transketolase and oxynitrilase, and combinatorial methods =
versus site-directed mutagenesis). =
We have assembled a notable group of speakers, discussion leaders, and =
poster presenters. Attached is a copy of the preliminary program. For =
additional information on the Conference including the most recent =
update of the program and the poster sessions we suggest that you =
connect to our World-Wide Web site at
http://w3.argotech.com/argotech/biocatalysis
If you do not have access to the World-Wide Web or need additional =
information, please contact me by e-mail at the address shown below and =
can send you additional information and applications forms.
We look forward to receiving your application to the conference.
Sincerely,
Paul van Eikeren
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D
Paul van Eikeren, Co-Chair
Vice President, Chemistry
Argonaut Technologies Inc.
887 Industrial Road, Suite G
San Carlos, CA 94070 USA
Voice: +1 415 598 1350 ext. 217
Fax: +1 415 598 1359
pvaneikeren at argotech.com74260.1024 at compuserve.com
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D
P R O G R A M I N F O R M A T I O N
(Updated on 25 March 1996)
=3D=3D Opening Session:
* Stanley Roberts (Liverpool, UK) Enzymic Baeyer Villiger Reaction
* J. John Holbrook (U. Bristol, UK) Getting the Products Off Enzymes =
Used in Bulk Chemoenzymic Synthesis
=3D=3D Structure and Engineering of Hydrolases for Organic Synthesis
* Sabine L. Flitsch (U. Edinburgh, UK) Design and Synthesis of =
Enzyme-Cleavable Linkers for Solid Phase Synthesis
* Guy G. Dodson (York U., UK) Nucleophilic Attack at the Carbonyl in =
Hydrolases: The Varying Stereochemistry at the Nucleophile
* Franz Effenberger (U. Stuttgart, Germany) New Results on Preparation =
and Application of Chiral Cyanohydrins
* Robert Menard (NRC Biotechnology Research Institute, Canada) Protein =
Engineering of Cysteine Proteases: From a Better Understanding of Their =
Function to Redesigning the Catalytic Activity
=3D=3D Molecular Evolution of Subtilisin
* Frances Arnold (California Institute of Technology, USA) Directed =
Evolution of p-Nitrobenzyl Esterase
* Marcus Ballinger (Genentech, USA) Subtilisin BPN Variants Designed for =
Cleavage of Multibasic Substrates
Multibasic Substrates =
* Volker Schellenberger (Genencor, USA) Directed evolution of a =
Bacillus protease
=3D=3D New Application of Hydrolases
* Herbert Waldmann (Karlsruhe, Germany) Bioorganic Synthesis and =
Biological Signal Transduction
* Milton Zmijewski (Lily, Indianapolis, USA) Enzymatic Removal of =
Protecting Groups in the Synthesis of Pharmaceuticals
* Kazuo Achiwa (Shizuoka U.) Lipase-Catalyzes Asymmetric Synthesis of =
Optically-Active Medicines: New Strategies and their Application
=3D=3D Discovery versus Engineering of New Enzymes
* John Arnett (Recombinant Biocatalysis, USA) Enzymes from Thermophilic =
Microorganisms
* Gunter Schneider (Karolinska Institute, Stockholm, Sweden) Toward =
Tailoring Enzymes for Asymmetric Synthesis: Protein Engineering of =
Transketolase
=3D=3D Aldolases and Glycosyl Transfer
* Eric Toone (Duke University) Pyruvate Aldolases
* Vladimir Kren (Czech Academy of Sciences) Enzymatic Glycosylation of =
Pharmacologically Active Compounds: Multienzymatic Approaches and New =
Enzymes
=3D=3D New Hydrolases
* Roland Furstoss (U. Aix-Marseille, France) Enantioselective =
Biotransformations with Epoxide Hydrolases
* Kenji Soda (Kyoto, Japan) 2-Haloacid Dehalogenases: Their Functions, =
Structures, and Applications
=3D=3D Oxidations
* Aleksey Zaks (Schering-Plough, Union, NJ, USA) Chloroperoxidase
* Bernhard Hauer (BASF AG, Ludwigshafen, Germany) Selection of =
Biocatalysts for the Preparation of Chiral/Chemical Building Blocks
* Roger Sheldon (Delft U. Netherlands) Enantioselective Aminolysis and =
Selective Oxidations Mediated by Chloroperoxidase
=3D=3D Large Scale Industrial Applications
* Kevin DiGregorio (Union Carbide, USA) Polyester Hydrolysis
* Robert Dicosimo (Dupont, Wilmington, DE, USA) Scale-Up of a =
Biocatalytic Route to N-Phosphonomethylglycine (Glyphosate) Using Whole =
Cell Transformants
